Efficacy

Efficacy of Tremfya (Guselkumab) for Psoriasis

Tremfya (guselkumab) is a medication approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is a monoclonal antibody that selectively blocks the protein interleukin-23 (IL-23), a key player in the pathogenesis of psoriasis. Clinical trials have demonstrated that Tremfya is effective in achieving significant skin clearance in many patients. For instance, in the VOYAGE 1 and 2 trials, over 70% of patients treated with guselkumab achieved at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at week 16, with continued efficacy over time.

Furthermore, the long-term efficacy of Tremfya has been supported by data showing sustained responses with continuous treatment. In extension phases of clinical trials, a high proportion of patients maintained their PASI 90 response through week 100. The safety and efficacy profile of Tremfya, along with the convenience of its dosing schedule, typically an initial dose followed by a dose every 8 weeks, makes it a valuable treatment option for many patients with psoriasis.

Efficacy of Wezlana (Ustekinumab-auub) for Psoriasis

Wezlana (ustekinumab-auub) is a biosimilar to the original biologic drug ustekinumab, which is marketed under the brand name Stelara. Biosimilars are highly similar to and have no clinically meaningful differences from an existing FDA-approved reference product. Ustekinumab targets the proteins interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in inflammatory and immune responses. Wezlana, like its reference product, is used for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy.

Clinical studies on ustekinumab have shown that it can lead to significant improvements in psoriasis symptoms. In pivotal trials, patients treated with ustekinumab experienced marked reductions in psoriasis severity, with many achieving a PASI 75 (75% improvement in PASI score) within 12 weeks of treatment. The efficacy of ustekinumab in psoriasis is well-established, with a substantial number of patients maintaining treatment response over time. As Wezlana is a biosimilar to ustekinumab, its efficacy in treating psoriasis is expected to be similar, providing patients with an additional treatment option.